mTOR阻害薬のパイプライン分析

◆英語タイトル:mTOR Inhibitors Therapeutics - Pipeline Analysis 2017, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
◆商品コード:PSM802121
◆発行会社(リサーチ会社):P&S Market Research
◆発行日:2017年12月1日
◆ページ数:124
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Group License(5名様閲覧用)USD3,250 ⇒換算¥357,500見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,750 ⇒換算¥852,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はP&S Market Research社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。P&S Market Research社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

The mechanistic/mammalian target of rapamycin (mTOR) is a serine threonine protein kinase, that belongs to the phosphatidylinositol-3-kinase-related kinase family. Molecules in this family have more than 2,500 amino acids, and they harbor a kinase domain at their C-terminals. It has been observed that the increasing prevalence of cancer along with its high healthcare cost, globally, has been driving the growth of mTOR inhibitors pipeline. For instance, the number of people living beyond cancer diagnosis reached around 14.5 million in 2014 and is expected to increase to 19 million, by 2024. In 2010, approximately $125 million was spent on cancer care in the U.S., and it is expected to reach $156 million, by 2020.
Other factors strengthening the mTOR inhibitors pipeline include smoking, obesity unhygienic food, and allergy. The study analyzed that mTOR inhibitors therapeutics pipeline comprises approximately 30 drug candidates in different stages of development.

Insights on pipeline segments

According to the research findings, most of the drug candidates that act as mTOR inhibitors are being developed as small molecules, further supported by the fact that small molecules have several advantages such as it can be manufactured with production rate higher than any other molecule types.

Positive Clinical Results of mTOR Inhibitors Therapeutics Candidates

The positive clinical results of mTOR inhibitors drug candidates is a key factor driving the pipeline growth. For instance, F. Hoffman-La-Roche AG has developed a drug candidate, ipatasertib, that acts as mTOR inhibitors. The Phase II clinical results (Study ID: NCT02162719) of the drug candidate were published in the Lancet Oncology journal. It has been observed that progression-free survival was longer in patients who received ipatasertib as compared in those who received placebo.

Technological Advancements for mTOR Inhibitors Therapeutics Drug Development

Most of the companies are developing innovative technologies for the synthesis or production of mTOR inhibitors. For instance, PHusis Therapeutics Inc. is using its computational modeling platform namely, PHuDock, that identify inhibitors of proteins which promotes the growth of cancer cells. Using PHuDock, X-ray structural information and surface plasmon resonance spectroscopic measurements of selected drug-like molecules, PHusis is rapidly and efficiently identifying agents involving toxicity studies, that selectively inhibit the activity of a number of these cancers driving proteins. PHuDock is applied to lead identification and optimization, as well as to predict the compounds off-target properties and toxicity, therefore delivering novel and highly effective agents with low toxicity.

These technologically advanced platforms enable the players in the pipeline to develop effective new therapies rapidly, that are cost effective and potentially have lower risk of toxicity, and relative to traditional approaches. Thus, these technological advancements act as a key driver for the pipeline growth.

Some of the key players involved in the development of mTOR inhibitors therapeutics include F. Hoffman-La-Roche AG, Pfizer Inc., and resTORbio Inc.

【レポートの目次】

Chapter 1. Research Background

1.1 Research Objectives

1.2 Definition

1.3 Research Scope

1.3.1 Pipeline Analysis by Phase

1.3.2 Pipeline Analysis by Molecule Type

1.3.3 Pipeline Analysis by Route of Administration

1.4 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.2 Primary Research

2.2.1 By Industry Participant

2.2.2 By Company Type

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

4.1 Overview

4.2 Key Drivers

4.2.1 Increasing Prevalence of Cancer and Rising Healthcare Cost

4.2.2 Technical Advancements

4.3 Key Barrier

4.3.1 Safety Concerns and Risk factors

4.4 mTOR Inhibitor Therapeutics Pipeline Analysis

4.4.1 Pipeline Analysis by Phase

4.4.2 Pipeline Analysis by Molecule Type

4.4.3 Pipeline Analysis by Route of Administration

4.4.4 Pipeline Analysis by Company

Chapter 5. mTOR Inhibitor Therapeutics Pipeline Analysis by Phase (2017) 30

5.1 Phase III

5.1.1 Ipatasertib

5.1.1.1 Clinical trials

5.1.1.2 Clinical results

5.1.1.3 Strategic developments

5.1.2 XXXX

5.1.2.1 Clinical trials

5.2 Phase II

5.2.1 LY3023414

5.2.1.1 Clinical trials

5.2.2 XXXX

5.2.2.1 Pre-Clinical studies

5.2.2.2 Clinical trials

5.2.2.3 Clinical results

5.2.2.4 Others

5.2.3 XXXX

5.2.3.1 Clinical trials

5.2.3.2 Strategic developments

5.2.4 XXXX

5.2.4.1 Clinical trials

5.2.4.2 Clinical results

5.2.4.3 Strategic developments

5.2.5 XXXX

5.2.5.1 Clinical trials

5.2.5.2 Strategic developments

5.2.5.3 Grant

5.2.5.4 Technology

5.2.6 XXXX

5.2.6.1 Clinical trials

5.2.6.2 Designation

5.2.7 XXXX

5.2.7.1 Clinical trials

5.2.7.2 Clinical results

5.2.8 XXXX

5.2.8.1 Pre-Clinical Studies

5.2.8.2 Clinical trials

5.2.8.3 Clinical results

5.2.8.4 Strategic developments

5.2.8.5 Designation

5.2.8.6 Grant

5.3 Phase I

5.3.1 VDC597

5.3.2 XXXX

5.3.2.1 Clinical trials

5.4 Pre-Clinical

5.4.1 VPE001

5.4.1.1 Strategic developments

5.4.2 XXXX

5.4.2.1 Pre-Clinical studies

5.4.2.2 Others

5.4.3 XXXX

5.4.3.1 Technology

5.4.3.2 Strategic developments

5.4.4 XXXX

5.4.4.1 Technology

5.4.5 XXXX

5.4.6 XXXX

5.4.6.1 Technology

5.4.6.2 Designation

5.4.7 XXXX

5.4.7.1 Others

5.4.7.2 Technology

5.4.8 XXXX

5.4.8.1 Pre-Clinical studies

5.4.8.2 Strategic developments

5.4.8.3 Technology

5.5 Discovery

5.5.1 VEA005

5.5.1.1 Strategic developments

5.5.2 XXXX

5.5.2.1 Strategic developments

5.5.3 XXXX

5.5.3.1 Strategic developments

5.5.4 XXXX

5.5.4.1 Strategic developments

5.5.5 XXXX

5.5.5.1 Strategic developments

5.5.5.2 Technology

5.5.6 XXXX

5.5.6.1 Others

5.5.7 XXXX

5.5.7.1 Technology

5.6 Unknown Phase

5.6.1 Non-Steroidal Small Molecule Drug

5.7 Discontinued

Chapter 6. Clinical Trials Analysis

6.1 Clinical Trials by Region for mTOR Inhibitors Therapeutics Pipeline Analysis 2017

6.2 Clinical Trials by Trial Status for mTOR Inhibitors Therapeutics Pipeline Analysis 2017

Chapter 7. Competitive Landscape

7.1 Key Players Benchmarking for mTOR inhibitors Therapeutics Pipeline

7.2 SWOT Analysis of mTOR inhibitor Therapeutics Pipeline

7.2.1 Strengths

7.2.2 Weaknesses

7.2.3 Opportunities

7.2.4 Threats

Chapter 8. Company Profiles

8.1 Eli Lilly & Company

8.1.1 Business Overview

8.1.2 Product & Service Offerings

8.2 AstraZeneca Plc

8.2.1 Business Overview

8.2.2 Product & Service Offerings

8.3 Company 3

8.3.1 Business Overview

8.3.2 Product & Service Offerings

8.4 Company 4

8.4.1 Business Overview

8.4.2 Product & Service Offerings

8.5 Company 5

8.5.1 Business Overview

8.5.2 Product & Service Offerings

8.6 Company 6

8.6.1 Business Overview

8.6.2 Product & Service Offerings

8.7 Company 7

8.7.1 Business Overview

8.7.2 Product & Service Offerings

8.8 Company 8

8.8.1 Business Overview

8.8.2 Product & Service Offerings

8.9 Company 9

8.9.1 Business Overview

8.9.2 Product & Service Offerings

8.1 Company 10

8.10.1 Business Overview

8.10.2 Product & Service Offerings

Chapter 9. Appendix

9.1 Abbreviations

9.2 Related Reports

LIST OF TABLES

TABLE 1 PIPELINE ANALYSIS OF MTOR THERAPEUTICS, BY COMPANY (2017)

TABLE 2 DESCRIPTION OF IPATASERTIB

TABLE 3 CLINICAL TRIALS OF IPATASERTIB

TABLE 4 DESCRIPTION OF XXXX

TABLE 5 CLINICAL TRIALS OF XXXX

TABLE 6 DESCRIPTION OF LY3023414

TABLE 7 CLINICAL TRIALS OF LY3023414

TABLE 8 DESCRIPTION OF XXXX

TABLE 9 CLINICAL TRIALS OF XXXX

TABLE 10 DESCRIPTION OF XXXX

TABLE 11 DESCRIPTION OF XXXX

TABLE 12 CLINICAL TRIALS OF XXXX

TABLE 13 DESCRIPTION OF XXXX

TABLE 14 CLINICAL TRIALS OF XXXX

TABLE 15 DESCRIPTION OF XXXX

TABLE 16 CLINICAL TRIALS OF XXXX

TABLE 17 DESCRIPTION OF XXXX

TABLE 18 CLINICAL TRIALS OF XXXX

TABLE 19 DESCRIPTION OF XXXX

TABLE 20 CLINICAL TRIALS OF XXXX

TABLE 21 DESCRIPTION OF VDC597

TABLE 22 DESCRIPTION OF XXXX

TABLE 23 CLINICAL TRIALS OF XXXX

TABLE 24 DESCRIPTION OF VPE001

TABLE 25 DESCRIPTION OF XXXX

TABLE 26 DESCRIPTION OF XXXX

TABLE 27 DESCRIPTION OF XXXX

TABLE 28 DESCRIPTION OF XXXX

TABLE 29 DESCRIPTION OF XXXX

TABLE 30 DESCRIPTION OF XXXX

TABLE 31 DESCRIPTION OF XXXX

TABLE 32 DESCRIPTION OF VEA005

TABLE 33 DESCRIPTION OF XXXX

TABLE 34 DESCRIPTION OF XXXX

TABLE 35 DESCRIPTION OF XXXX

TABLE 36 DESCRIPTION OF XXXX

TABLE 37 DESCRIPTION OF XXXX

TABLE 38 DESCRIPTION OF XXXX

TABLE 39 DESCRIPTION OF NON-STEROIDAL SMALL MOLECULE DRUG

TABLE 40 DESCRIPTION OF DISCONTINUED DRUGS

TABLE 41 ELI LILLY & COMPANY – AT A GLANCE

TABLE 42 ASTRAZENECA PLC – AT A GLANCE

TABLE 43 COMPANY 3 – AT A GLANCE

TABLE 44 COMPANY 4 – AT A GLANCE

TABLE 45 COMPANY 5 – AT A GLANCE

TABLE 46 COMPANY 6 – AT A GLANCE

TABLE 47 COMPANY 7 – AT A GLANCE

TABLE 48 COMPANY 8 – AT A GLANCE

TABLE 49 COMPANY 9 – AT A GLANCE

TABLE 50 COMPANY 10 – AT A GLANCE

LIST OF FIGURES

FIG 1 RESEARCH METHODOLOGY

FIG 2 SPLIT OF PRIMARY AND SECONDARY RESEARCH

FIG 3 BREAKDOWN OF PRIMARY RESEARCH BY INDUSTRY PARTICIPANT

FIG 4 BREAKDOWN OF PRIMARY RESEARCH BY COMPANY TYPE

FIG 5 CELL SIGNALING PATHWAYS

FIG 6 GENE RELATED TO MTOR

FIG 7 MTOR INHIBITOR THERAPEUTICS UNDER DEVELOPMENT (2017)

FIG 8 MTOR INHIBITOR THERAPEUTICS PIPELINE SPLIT, BY MOLECULE TYPE (2017)

FIG 9 MTOR THERAPEUTIC PIPELINE SPLIT, BY ROUTE OF ADMINISTRATION (2017)

FIG 10 BREAKDOWN OF CLINICAL TRIALS, BY REGION

FIG 11 BREAKDOWN OF CLINICAL TRIALS, BY TRIAL STATUS

FIG 12 KEY PLAYERS BENCHMARKING

FIG 13 SWOT ANALYSIS



【レポートのキーワード】

mTOR阻害薬

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ mTOR阻害薬のパイプライン分析(mTOR Inhibitors Therapeutics - Pipeline Analysis 2017, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆